Janssen’s Stelara Fails to Show Superiority over AbbVie’s Humira in P-IIIb SEAVUE Study for Crohn’s Disease, Presented at DDW 2021

 Janssen’s Stelara Fails to Show Superiority over AbbVie’s Humira in P-IIIb SEAVUE Study for Crohn’s Disease, Presented at DDW 2021

Shots:

  • The P-IIIb SEAVUE study involves assessing Stelara(6 mg/kg, IV at baseline, then 90mg, SC, q8w) vs Humira (160/80mg, SC at baseline, then 40mg, SC, q2w) in the treatment of 386 biologic-naïve patients in a ratio (1:1) with mod. to sev. active CD
  • The data demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response, and endoscopic response through 1yr., although the 1EPs of statistical superiority was not demonstrated
  • Additional abstracts of data are also being presented at DDW, which include safety of Stelara in IBD along with long term data of Stelara in the IM-UNITI study with RWE of the therapy for CD

Click here to­ read full press release/ article | Ref: J&J | Image: Ars Technica

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post